WO2001036977A3 - Identification of disease markers involving mass-based-separation - Google Patents

Identification of disease markers involving mass-based-separation Download PDF

Info

Publication number
WO2001036977A3
WO2001036977A3 PCT/US2000/031492 US0031492W WO0136977A3 WO 2001036977 A3 WO2001036977 A3 WO 2001036977A3 US 0031492 W US0031492 W US 0031492W WO 0136977 A3 WO0136977 A3 WO 0136977A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
separation
disease markers
mass
methods
Prior art date
Application number
PCT/US2000/031492
Other languages
French (fr)
Other versions
WO2001036977A2 (en
WO2001036977A8 (en
Inventor
Brynmor A Watkins
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech Inc filed Critical Matritech Inc
Priority to AU16152/01A priority Critical patent/AU1615201A/en
Priority to JP2001538814A priority patent/JP2003528296A/en
Priority to CA002391212A priority patent/CA2391212A1/en
Priority to EP00978722A priority patent/EP1240521A2/en
Publication of WO2001036977A2 publication Critical patent/WO2001036977A2/en
Publication of WO2001036977A3 publication Critical patent/WO2001036977A3/en
Publication of WO2001036977A8 publication Critical patent/WO2001036977A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention provides mass spectroscopic-ased methods and compositions for identifying disease markers, for example, cancer markers, in a mammal. In particular, the mass-spectroscopic-based methods and compositions facilitate the rapid identification of cancer markers from tissue or body fluid samples. The cancer markers, once identified, can then be used as targers in methods for detecting or treating cancer in the mammal.
PCT/US2000/031492 1999-11-16 2000-11-16 Identification of disease markers involving mass-based-separation WO2001036977A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU16152/01A AU1615201A (en) 1999-11-16 2000-11-16 Methods and compositions for identifying disease markers
JP2001538814A JP2003528296A (en) 1999-11-16 2000-11-16 Identification of disease markers including mass-based separation
CA002391212A CA2391212A1 (en) 1999-11-16 2000-11-16 Methods and compositions for identifying disease markers
EP00978722A EP1240521A2 (en) 1999-11-16 2000-11-16 Identification of disease markers involving mass-based-separation

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US16567399P 1999-11-16 1999-11-16
US60/165,673 1999-11-16
US17217099P 1999-12-17 1999-12-17
US60/172,170 1999-12-17
US17886000P 2000-01-27 2000-01-27
US60/178,860 2000-01-27
US20172100P 2000-05-03 2000-05-03
US60/201,721 2000-05-03
US09/709,947 US6936424B1 (en) 1999-11-16 2000-11-10 Materials and methods for detection and treatment of breast cancer
US09/709,954 2000-11-10

Publications (3)

Publication Number Publication Date
WO2001036977A2 WO2001036977A2 (en) 2001-05-25
WO2001036977A3 true WO2001036977A3 (en) 2001-11-22
WO2001036977A8 WO2001036977A8 (en) 2002-01-24

Family

ID=30449666

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/031492 WO2001036977A2 (en) 1999-11-16 2000-11-16 Identification of disease markers involving mass-based-separation
PCT/US2000/031483 WO2001036470A2 (en) 1999-11-16 2000-11-16 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031483 WO2001036470A2 (en) 1999-11-16 2000-11-16 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides

Country Status (9)

Country Link
US (2) US6936424B1 (en)
EP (2) EP1240521A2 (en)
JP (2) JP2004500056A (en)
AT (1) ATE354588T1 (en)
AU (2) AU1658901A (en)
CA (2) CA2391212A1 (en)
DE (1) DE60033555T2 (en)
ES (1) ES2282149T3 (en)
WO (2) WO2001036977A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
AUPQ886100A0 (en) * 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
CA2320549A1 (en) * 2000-09-25 2002-03-25 Eastern Virginia Medical College Biomarkers of transitional cell carcinoma of the bladder
EP1425575A4 (en) * 2001-08-03 2004-09-29 Biotron Ltd A novel cancer marker and uses therefor in the diagnosis of cancer
US6756586B2 (en) 2001-10-15 2004-06-29 Vanderbilt University Methods and apparatus for analyzing biological samples by mass spectrometry
US20050092910A1 (en) * 2001-12-08 2005-05-05 Scott Geromanos Method of mass spectrometry
DE10296200D2 (en) * 2001-12-21 2004-11-04 Biovision Ag Methods for diagnosing breast cancer, associated peptides and their uses
AU2003217954A1 (en) * 2002-03-06 2003-09-22 Johns Hopkins University Use of biomarkers to detect breast cancer
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
ES2291750T3 (en) 2002-12-20 2008-03-01 F. Hoffmann-La Roche Ag USE OF NICOTINAMIDE-N-METHYLTRANSPHERASE AS A COLORRECTAL CANCER MARKER.
EP1613966A2 (en) 2003-04-08 2006-01-11 Colotech A/S A method for detection of colorectal cancer in human samples
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050037331A1 (en) * 2003-08-13 2005-02-17 William Galbraith Apparatuses and methods for reducing albumin in samples
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP1794593A2 (en) * 2004-09-21 2007-06-13 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
JP2008535771A (en) * 2004-12-14 2008-09-04 アプレラ コーポレイション Cationic liposome and method of using the same
ATE501267T1 (en) 2005-01-06 2011-03-15 Eastern Virginia Med School APOLIPOPROTEIN A-II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER
DE602006013109D1 (en) * 2005-03-14 2010-05-06 Japan Health Science Found MARKER PROTEIN FOR USE IN THE DIAGNOSIS OF PANCREATIC CANCER
US7749445B2 (en) 2005-05-02 2010-07-06 Bioscale, Inc. Method and apparatus for analyzing bioprocess fluids
US7648844B2 (en) 2005-05-02 2010-01-19 Bioscale, Inc. Method and apparatus for detection of analyte using an acoustic device
US20100173788A1 (en) * 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
JP2009509169A (en) * 2005-09-19 2009-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ Biomarkers for prostate cancer
JP5199101B2 (en) * 2005-10-13 2013-05-15 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー Methods for developing biomolecule assays
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US8354280B2 (en) 2007-09-06 2013-01-15 Bioscale, Inc. Reusable detection surfaces and methods of using same
WO2009075864A1 (en) * 2007-12-11 2009-06-18 New York University School Of Medicine Methods for detecting colon carcinoma
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
JP2013502201A (en) * 2009-08-21 2013-01-24 オンコセラピー・サイエンス株式会社 CSTF2 as a target gene for the treatment and diagnosis of lung cancer
AU2012261953A1 (en) * 2011-06-03 2013-12-12 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
EP3256040A4 (en) * 2015-02-11 2018-08-08 Abbott Diabetes Care Inc. Methods, devices and systems for distinguishing cancerous and non-cancerous tissue
US20170168055A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. SRM/MRM Assays
EP3614909B1 (en) * 2017-04-28 2024-04-03 Masimo Corporation Spot check measurement system
CN107677825B (en) * 2017-10-06 2019-04-23 汉氏联合（天津）干细胞研究院有限公司 A kind of tumor diagnosis composition for diagnosis of cervical cancer and the purposes for being used to prepare diagnostic kit
WO2021026172A1 (en) 2019-08-05 2021-02-11 Seer, Inc. Systems and methods for sample preparation, data generation, and protein corona analysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632521A1 (en) * 1996-08-13 1998-02-19 Forssmann Wolf Georg Isolating peptide(s) from body fluids, tissues and cell supernatant
WO1998007036A1 (en) * 1996-08-13 1998-02-19 Biovision Gmbh & Co. Kg Process for determining the status of an organism by peptide measurement

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264550A (en) 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
US5561222A (en) 1989-11-15 1996-10-01 Duke University RNA-binding proteins useful for the control of cellular genetic processing and expression
EP0460607A3 (en) 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
ATE242485T1 (en) 1993-05-28 2003-06-15 Baylor College Medicine METHOD AND MASS SPECTROMETER FOR THE DESORPTION AND IONIZATION OF ANALYTES
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
KR970705645A (en) 1995-07-03 1997-10-09 에프. 지. 엠. 헤르만스／이. 에이치 리링크 A METHOD FOR DETERMINING THE INTEGRITY OF NUCLEIC ACID
US5962242A (en) 1995-09-19 1999-10-05 Immuna Care Corporation Methods of predicting estrogen-dependent osteopenia
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US7008778B1 (en) * 1997-02-03 2006-03-07 Human Genome Sciences, Inc. Breast cancer specific gene 1
CA2284642A1 (en) 1997-03-21 1998-10-01 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of breast cancer
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999039204A1 (en) 1998-02-02 1999-08-05 Novadx Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix
US6410692B2 (en) 1998-02-02 2002-06-25 Novadx, Inc. Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
EP1794593A2 (en) * 2004-09-21 2007-06-13 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632521A1 (en) * 1996-08-13 1998-02-19 Forssmann Wolf Georg Isolating peptide(s) from body fluids, tissues and cell supernatant
WO1998007036A1 (en) * 1996-08-13 1998-02-19 Biovision Gmbh & Co. Kg Process for determining the status of an organism by peptide measurement

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHONG BATHSHEBA E ET AL: "Rapid screening of protein profiles of human breast cancer cell lines using non-porous reversed-phase high performance liquid chromatography separation with matrix-assisted laser desorption/ionization time-of-flight mass spectral analysis.", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 13, no. 18, 1999, pages 1808 - 1812, XP001006015, ISSN: 0951-4198 *
HABETS W J ET AL: "ANALYSIS OF A COMPLEMENTARY DNA CLONE EXPRESSING A HUMAN AUTOIMMUNE ANTIGEN FULL-LENGTH SEQUENCE OF THE U2 SMALL NUCLEAR RNA-ASSOCIATED B ANTIGEN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 84, no. 8, 1987, 1987, pages 2421 - 2425, XP002169270, ISSN: 0027-8424 *
JUNGBLUT P R ET AL: "PROTEOMICS IN HUMAN DISEASE: CANCER, HEART AND INFECTIOUS DISEASES", ELECTROPHORESIS,DE,WEINHEIM, vol. 20, no. 10, July 1999 (1999-07-01), pages 2100 - 2110, XP000870393, ISSN: 0173-0835 *
RASMUSSEN HANNE H ET AL: "Towards a comprehensive database of proteins from the urine of patients with bladder cancer.", JOURNAL OF UROLOGY, vol. 155, no. 6, 1996, pages 2113 - 2119, XP001006003, ISSN: 0022-5347 *
WATKINS B ET AL: "Identification of serum nuclear matrix protein markers of breast cancer using surface enhanced laser desorption-ionization (SELDI) mass spectroscopy.", BREAST CANCER RESEARCH AND TREATMENT, vol. 64, no. 1, November 2000 (2000-11-01), 23rd Annual San Antonia Breast Cancer Symposium;San antonio, Texas, USA; December 06-09, 2000, pages 98, XP001001191, ISSN: 0167-6806 *
WATKINS B ET AL: "Surface enhanced laser desorption-ionization (SELDI) mass spectroscopy in the discovery of serum markers for breast cancer.", TUMOR BIOLOGY, vol. 21, no. Supplement 1, September 2000 (2000-09-01), 28th Meeting of the International Society for Oncodevelopmental Biology and Medicine;Munich, Germany; September 08-13, 2000, pages 35, XP001001193, ISSN: 1010-4283 *

Also Published As

Publication number Publication date
US20060160154A1 (en) 2006-07-20
CA2390607A1 (en) 2001-05-25
JP2004500056A (en) 2004-01-08
ATE354588T1 (en) 2007-03-15
EP1232177A2 (en) 2002-08-21
US6936424B1 (en) 2005-08-30
WO2001036977A2 (en) 2001-05-25
AU1615201A (en) 2001-05-30
WO2001036470A2 (en) 2001-05-25
WO2001036470A3 (en) 2002-01-24
EP1240521A2 (en) 2002-09-18
AU1658901A (en) 2001-05-30
ES2282149T3 (en) 2007-10-16
DE60033555D1 (en) 2007-04-05
DE60033555T2 (en) 2007-11-29
WO2001036977A8 (en) 2002-01-24
EP1232177B1 (en) 2007-02-21
JP2003528296A (en) 2003-09-24
CA2391212A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001036977A8 (en) Identification of disease markers involving mass-based-separation
WO2000061808A3 (en) Methods for detecting nucleic acids indicative of cancer
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
MXPA02006145A (en) Method for isolation of rna from formalinfixed paraffinembedded tissue specimens.
WO2001051654A3 (en) Methods and kits for identifying elite event gat-zm1 in biological samples
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
EP1319178A4 (en) Method of identifying cancer markers and uses therefor in the diagnosis of cancer
WO2005052542A3 (en) Method and composition useful for determining fk 506
WO2000020846A8 (en) Method for imaging tissue
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
MXPA01011182A (en) Methods, compositions and kits for biological indicator of sterilization.
WO2001025791A3 (en) Prostate cancer marker proteins
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2001098539A3 (en) Gene markers for lung cancer
AU5947701A (en) Methods for identification, diagnosis, and treatment of breast cancer
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 21/2001 UNDER (30) REPLACE "NOT FURNISHED" BY "09/709954"

WWE Wipo information: entry into national phase

Ref document number: 2391212

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 16152/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 538814

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000978722

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000978722

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000978722

Country of ref document: EP